Amerikanische Gesellschaft für Hirudotherapie

Salvage of pedicled anterolateral thigh flap for closure of a massive full-thickness abdominal wall defect using modified Perez protocol for chemical leeching

Babalola OF, Udensi R (2026) · Journal of Surgical Case Reports · n=1

RCT-EvidenzdetailsStudienreferenz
GRADE Sehr niedrigUnzureichende Evidenz
Stichprobengröße dieser Studie im Vergleich zu anderen venous-congestion-flap-StudienMarquard JM 20251215Bishop JL 2023843Doğan S 2024570Troeltzsch M 2016330Kucur C 2015260Wang ZD 2022210Lehnhardt M 202196Kruer RM 201459Mozafari N 201056Babalola OF 20261
Diese Studie (hervorgehoben) nach Stichprobengröße neben anderen indexierten venous-congestion-flap-Studien. Größere Studien haben im Allgemeinen ein höheres statistisches Gewicht.

Studienprofil

Design
single case report of pedicled anterolateral thigh (ALT) fasciocutaneous flap salvage using the modified Perez protocol for chemical leeching to manage diffuse venous congestion after post-tumor-resection full-thickness abdominal wall defect coverage; 14-day chemical leeching protocol with slight dosage modification for flap volume (Department of Surgery, Federal Teaching Hospital Ido-Ekiti, and Department of Surgery, Afe Babalola University, Ekiti State, Nigeria)
Stichprobengröße (n)
1
Intervention
Modified Perez protocol for chemical leeching applied for 14 days following postoperative day 2 diagnosis of diffuse venous congestion of the pedicled ALT flap; dosage modified to account for the volume of flap tissue; concurrent management with standard postoperative care
Komparator
Not applicable - single-patient case report; comparison to medicinal-leech therapy is narrative only
Primärer Endpunkt
Partial flap salvage and avoidance of visceral exposure of the abdominal wall defect
Primäres Ergebnis
Partial salvage of the flap was achieved by postoperative day 14 with no visceral exposure; residual granulation on the flap was resurfaced with a meshed split-thickness skin graft; authors affirmed the reliability of the Perez chemical-leeching protocol for managing pedicled flap venous congestion; case illustrates an alternative pharmacologic-leech strategy in resource settings where medicinal leech supply may be limited
Follow-up-Dauer
14-day chemical leeching protocol plus subsequent skin grafting and follow-up

Wichtigste Ergebnisse

  • African (Nigerian) academic-center case report of the modified Perez chemical-leeching protocol for pedicled ALT flap salvage
  • 14-day chemical leeching protocol with dosage modification for flap volume — practical resource-setting alternative
  • Partial salvage achieved with no visceral exposure — clinically meaningful outcome despite incomplete flap survival
  • Adds geographic diversity (Nigeria) to the broader leech-alternative literature
  • Supports continued investigation of chemical-leeching protocols as a resource-setting alternative to medicinal-leech therapy

Einschränkungen

  • Single case (n=1) - cannot establish generalizable efficacy
  • Modified Perez protocol details not fully specified in abstract
  • No randomized comparator to standard medicinal leech therapy
  • Outcome adjudication by treating team only
  • Resource-setting context may not generalize to all institutional environments

Klinische Implikationen

Babalola 2026 documents successful use of the modified Perez chemical-leeching protocol for pedicled ALT flap venous congestion salvage in a Nigerian academic center. For US clinicians, the trial does not directly change current K040187 medicinal-leech practice but adds to the broader 'pharmacologic leeching' translational literature (alongside Harun 2018 bivalirudin, Ünal 2025 leech saliva extract) and provides a resource-setting alternative reference for clinicians practicing in environments where medicinal-leech supply chains may be limited. The trial is hypothesis-generating and supports continued investigation of chemical and pharmacologic leech alternatives.

Verwandte Studien

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Freigabe für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.